Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy

European Journal of Cancer

Volumn 45, Issue 17, 2009, Pages 2992-2999

  Gertler, Ralf ^a   Rosenberg, Robert ^a   Schuster, Tibor ^a   Friess, Helmut ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adjuvant therapy; Colon cancer; Prognosis; Stage I; Stage II; Surgery; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMICOLECTOMY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGMOIDECTOMY; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS;

EID: 70350576877     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.07.008     Document Type: Article

References (37)

1. Nelson H., Petrelli N., Carlin A., et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93 (2001) 583-596
2. Sobin L.H., and Wittekind C. TNM classification of malignant tumors. 5th ed. (1997), Wiley-Liss, New York
3. Greene F.L., Page D.L., Fleming I.D., et al. AJCC cancer staging manual. 6th ed. (2002), Springer-Verlag, New York
4. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
5. Benson III A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004) 3408-3419
6. Figueredo A., Germond C., Maroun J., et al. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1 (1997) 379-392
7. Figueredo A., Charette M.L., Maroun J., et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22 (2004) 3395-3407
8. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and how much?. J Clin Oncol 22 (2004) 1797-1806
9. International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 Colon Cancer. J Clin Oncol 1999;17:1356-63.
10. Schrag D., Rifas-Shiman S., Saltz L., et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20 (2002) 3999-4005
11. Schmiegel W., Pox C., Reinacher-Schick A., et al. S3-guideline "Colorectal Cancer" 2004/2008. Z Gastroenterol 46 (2008) 1-73
12. Saville D.J. Multiple comparison procedures: the practical solution. The American Statistician 44 (1990) 174-180
13. Nauta R., Stablein D.M., and Holyoke E.D. Survival of patients with stage B2 colon carcinoma: the Gastrointestinal Tumour Study Group experience. Arch Surg 124 (1989) 180-182
14. O'Connell J.B., and Maggard MA K.O.C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96 (2004) 1420-1425
15. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 322 (1990) 352-358
16. André T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 350 (2004) 2343-2351
17. Taal B.G., Van Tinteren H., Zoetmulder F.A., et al. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Brit J Cancer 85 (2001) 1437-1443
18. Sargent D.J., Golberg R.M., Jacobsen S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colo cancer in elderly patients. New Engl J Med 345 (2001) 1091-1097
19. Wolmark N., Rockette H., Wickerham D.L., et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol 8 (1990) 1466-1475
20. Mamounas E., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17 (1999) 1349-1355
21. Liver Infusion Meta-analysis Group: portal vein chemotherapy for colorectal cancer:a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 89 (1997) 497-505
22. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020-9.
23. Sobin L.H., and Wittekind C. TNM classification of malignant tumors. 5th ed. (1997), Wiley-Liss, New York
24. Sobin L.H., and Greene F.L. TNM classification: clarification of number of regional lymph nodes for pN0. Cancer 92 (2001) 452
25. Buyse M., and Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28 (2001) 20-24
26. Sobrero A., and Köhne C.H. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer?. Lancet Oncol 7 (2006) 515-517
27. Swanson R.S., Compton C.C., Stewart A.K., et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10 (2003) 65-71
28. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21 (2003) 2912-2919
29. Quah H.M., Chou J.F., Gonen M., et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 51 (2008) 503-507
30. Compton C.C., Fielding L.P., Burgart L.J., et al. Prognostic factors in colorectal ancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124 (2000) 979-994
31. Galandiuk S., Wieand H.S., Moertel C.G., et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 174 (1992) 27-32
32. Gertler R., Rosenberg R., Stricker D., et al. Telomere length and hTERT expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 22 (2004) 1807-1814
33. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based chemotherapy for colon cancer. New Engl J Med 349 (2003) 247-257
34. Wolmark N., Fisher B., Wieand H.S., et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199 (1984) 375-382
35. Wolmark N., Wieand H.S., Rockette H.E., et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 198 (1983) 743-752
36. Steinberg S.M., Barkin J.S., Kaplan R.S., et al. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 57 (1986) 1866-1870
37. Witzig T.E., Loprinzi C.L., Gancheroff N.J., et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68 (1991) 879-888